421 related articles for article (PubMed ID: 23055000)
1. Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.
Teixeira AL; Diniz BS; Campos AC; Miranda AS; Rocha NP; Talib LL; Gattaz WF; Forlenza OV
Neuromolecular Med; 2013 Mar; 15(1):115-21. PubMed ID: 23055000
[TBL] [Abstract][Full Text] [Related]
2. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
[TBL] [Abstract][Full Text] [Related]
3. The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia.
Dukic L; Simundic AM; Martinic-Popovic I; Kackov S; Diamandis A; Begcevic I; Diamandis EP
Clin Biochem; 2016 Feb; 49(3):213-8. PubMed ID: 26515085
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.
Xu ZP; Yang SL; Zhao S; Zheng CH; Li HH; Zhang Y; Huang RX; Li MZ; Gao Y; Zhang SJ; Zhan PY; Zhang LF; Deng L; Wei S; Liu YC; Ye JW; Ren HJ; Li N; Kong CX; Wang X; Fang L; Zhou QZ; Jiang HW; Li JR; Wang Q; Ke D; Liu GP; Wang JZ
EBioMedicine; 2016 Mar; 5():105-13. PubMed ID: 27077117
[TBL] [Abstract][Full Text] [Related]
5. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
[TBL] [Abstract][Full Text] [Related]
6. Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects.
Forlenza OV; Miranda AS; Guimar I; Talib LL; Diniz BS; Gattaz WF; Teixeira AL
J Alzheimers Dis; 2015; 46(2):423-9. PubMed ID: 25737042
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
[TBL] [Abstract][Full Text] [Related]
8. Low platelet iPLA₂ activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study.
Gattaz WF; Talib LL; Schaeffer EL; Diniz BS; Forlenza OV
J Neural Transm (Vienna); 2014 Feb; 121(2):193-200. PubMed ID: 24036895
[TBL] [Abstract][Full Text] [Related]
9. Serum Adiponectin in Alzheimer's Disease (AD): Association with AD Biomarkers and Cognitive Outcome.
Kim H; Jun S; Kim BS; Kim IJ;
J Alzheimers Dis; 2021; 84(3):1163-1172. PubMed ID: 34633322
[TBL] [Abstract][Full Text] [Related]
10. APOEɛ4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimer's Disease.
Cardoso R; Lemos C; Oliveiros B; Almeida MR; Baldeiras I; Pereira CF; Santos A; Duro D; Vieira D; Santana I; Oliveira CR
J Alzheimers Dis; 2020; 78(2):587-601. PubMed ID: 33016906
[TBL] [Abstract][Full Text] [Related]
11. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.
Lacour A; Espinosa A; Louwersheimer E; Heilmann S; Hernández I; Wolfsgruber S; Fernández V; Wagner H; Rosende-Roca M; Mauleón A; Moreno-Grau S; Vargas L; Pijnenburg YA; Koene T; Rodríguez-Gómez O; Ortega G; Ruiz S; Holstege H; Sotolongo-Grau O; Kornhuber J; Peters O; Frölich L; Hüll M; Rüther E; Wiltfang J; Scherer M; Riedel-Heller S; Alegret M; Nöthen MM; Scheltens P; Wagner M; Tárraga L; Jessen F; Boada M; Maier W; van der Flier WM; Becker T; Ramirez A; Ruiz A
Mol Psychiatry; 2017 Jan; 22(1):153-160. PubMed ID: 26976043
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults.
Mangialasche F; Solomon A; Kåreholt I; Hooshmand B; Cecchetti R; Fratiglioni L; Soininen H; Laatikainen T; Mecocci P; Kivipelto M
Exp Gerontol; 2013 Dec; 48(12):1428-35. PubMed ID: 24113154
[TBL] [Abstract][Full Text] [Related]
14. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
15. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
[TBL] [Abstract][Full Text] [Related]
16. Impact of serum leptin and adiponectin levels on brain infarcts in patients with mild cognitive impairment and Alzheimer's disease: a longitudinal analysis.
Carbone G; Bencivenga L; Santoro MA; De Lucia N; Palaia ME; Ercolano E; Scognamiglio F; Edison P; Ferrara N; Vitale DF; Rengo G; Femminella GD
Front Endocrinol (Lausanne); 2024; 15():1389014. PubMed ID: 38686200
[TBL] [Abstract][Full Text] [Related]
17. Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study.
Letra L; Matafome P; Rodrigues T; Duro D; Lemos R; Baldeiras I; Patrício M; Castelo-Branco M; Caetano G; Seiça R; Santana I
J Alzheimers Dis; 2019; 67(2):725-735. PubMed ID: 30689587
[TBL] [Abstract][Full Text] [Related]
18. The Effect of the APOE ε2ε4 Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Non-Latino Whites.
Ren D; Lopez OL; Lingler JH; Conley Y
J Am Geriatr Soc; 2020 May; 68(5):1044-1049. PubMed ID: 32017008
[TBL] [Abstract][Full Text] [Related]
19. Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment.
Llano DA; Devanarayan V;
J Alzheimers Dis; 2021; 80(1):311-319. PubMed ID: 33523012
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
